Compared with other breast cancer subtypes, TNBC exhibits stronger immunogenicity, abundant tumor-infiltrating lymphocytes (TILs), higher programmed cell death ligand 1 (PD-L1) expression and tumor mutation burden (TMB) (2, 11, 12), numerous explorations on adding ICIs to the therapeutic arsenal of TNBC have acquired inspiring feedback (13–15). This evidence concerns the gene CD274 and breast cancer.